Medpal (MPAL · LSE)

ConsumerHealthcareTechnologyLSE

Data‑Driven Healthcare in Action

A freemium health data platform with a rare NHS Distance Selling Pharmacy licence, converting 1m+ expected trial users into premium subscribers and high‑margin digital pharmacy demand across GLP‑1 and broader clinical services.

Medpal AI PLC

MPAL: LSE

6.00 GBp

+20.00%

year to date

Market Cap£42.79M

Avg Volume53.09M

PriceGBp6.00+15.38%

Pricing delayed 20 minutes Sep 7, 2026, 12:00 AM

Bull case for Medpal

The Spotify of Health Data
Aggregates 100+ devices into one AI-driven app, with Epassi unlocking 1m+ trial users
Monetising AI Health with NHS Pharmacy
NHS contract secured, GLP-1 offering live, and AI triage via WhatsApp deployed
Freemium Flywheel with Real Revenue
High engagement cohorts, premium pricing, and strong early conversion metrics

Bear case for Medpal

Execution Risk
Freemium conversion or pharmacy ramp slower than expected
Tech Arms Race
Better-funded rivals out-innovate or out-market MedPal
Regulatory Drag
AI or health tech regulations tighten unexpectedly